Obeldesivir (GS-5245) is an investigational oral antiviral drug that shows promise in treating various coronaviruses, including SARS, MERS, and SARS-CoV-2 (COVID-19). Developed through a partnership between Gilead Sciences and researchers at the University of North Carolina, the drug has demonstrated effectiveness in reducing viral replication and disease severity in mice. While a recent Phase 3 clinical trial did not meet its primary endpoint, the drug showed no safety concerns. Obeldesivir has the potential to be an effective broad-spectrum antiviral medication that can be taken orally, making it a valuable tool in future pandemic preparedness efforts.
Source link
Novel small molecule oral antiviral could be a game-changer in the fight against future pandemics
